Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Blood
; 132(23): 2456-2464, 2018 12 06.
Article
in En
| MEDLINE
| ID: mdl-30249784
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
High-Throughput Nucleotide Sequencing
/
Multiple Myeloma
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Blood
Year:
2018
Document type:
Article
Affiliation country:
Country of publication: